Webinar
Global Strategies for Accelerating Time to Market for Emerging Biopharmas
calendar

May 27, 2021

Calendar
clock

11:00am - 12:30pm

(GMT+08:00)

Register

View all IQVIA events

Emerging biopharma (EBP) and biotech companies have emerged as critical drivers of innovation, representing over 80% of early-stage research and over 70% of late-stage research globally. They are pushing the boundaries of science to deliver breakthrough therapies to patients. With over 140 new EBPs founded in China alone since 2010, and more than 60% of all Phase I to III clinical trials commenced in Japan and Asia Pacific (JAPAC) in 2019, the JAPAC region is fast becoming a powerhouse of emerging biopharma.

IQVIA warmly invites you to join the discussion with industry experts across the region as we explore JAPAC opportunities, industry trends, and discuss key strategies to help EBP and biotech companies achieve their milestones across the clinical to commercial journey.

You can expect to hear industry leaders share insights on:

  • How are EBP and biotech companies different in their clinical development needs? What solutions can partners and vendors offer to address these needs?
  • What are the global pathways for EBPs and biotechs in JAPAC, and why should they consider their commercialization plans upfront in their early phase development?
  • How can global EBPs and biotechs adapt their strategies and accelerate time to market by capitalizing on the rapidly advancing clinical research capability and large patient populations in JAPAC?

At IQVIA, we understand that the needs of EBP and biotech companies are different to those of more established pharmaceutical companies. Which is why we are also excited to unveil the expansion of our successful global biotech offering into Japan and Asia Pacific.

We look forward to hosting you on the 27th of May as we explore “Global Strategies for Accelerating Time to Market for Emerging Biopharmas”, and don’t miss this chance to hear about IQVIA’s offering for EBPs and biotech companies.

Contact Us